UFP Technologies (UFPT) has been removed from the Russell 2000 Dynamic Index, a shift that can prompt rebalancing by index-tracking funds and influence how some investors view the stock’s role in diversified portfolios.

The index removal comes after a period of strong momentum for UFP Technologies, with a 30-day share price return of 19.78% and a 90-day share price return of 36.17%. The 5-year total shareholder return of 356.66% points to a very large long term gain.

If this index change has you reassessing your watchlist, it could be a good moment to broaden your search and check out the 20 top founder-led companies

With UFP Technologies now trading at $263.63 and sitting at a 29% discount to an estimated intrinsic value and a 23% discount to the current analyst price target, you have to ask: Is there still a buying opportunity here, or is the market already pricing in future growth?

Price-to-Earnings of 29.7x: Is it justified?

On a P/E of 29.7x, UFP Technologies trades at a level that sits below the 42x peer average but above the 26.2x average for the wider US Medical Equipment industry. For investors, that mix of cheaper than peers yet richer than the industry sets up an interesting question about how the market is weighing the company’s earnings profile.

The P/E ratio compares the current share price with earnings per share, so a higher multiple usually reflects the market paying more for each dollar of current earnings. For a medical packaging and device components business like UFP Technologies, that can reflect expectations around future earnings growth, the perceived durability of demand in its end markets, and the quality of its profit stream.

Here, the signals are mixed. The stock looks good value compared with its direct peer group on a P/E basis, yet it screens as expensive against the broader Medical Equipment industry and also against an estimated fair P/E of 22.3x. That fair P/E level is a benchmark the market could move towards if sentiment or growth expectations change, which is why some investors pay close attention to this gap.

Compared with peers on 42x earnings, UFP Technologies looks firmly cheaper, suggesting the market is not assigning it the same earnings multiple as that group. Compared with the industry on 26.2x, it instead trades at a premium, and relative to the estimated fair P/E of 22.3x, it looks stretched on this metric, implying investors are paying up versus what that fair ratio model implies.

Result: Price-to-Earnings of 29.7x (OVERVALUED)

However, UFP Technologies is tightly focused on medical and defense related end markets, so any slowdown in customer orders or pricing pressure could quickly challenge today’s valuation narrative.

Another view on UFP Technologies using cash flows

The earlier P/E workup suggested UFP Technologies looks expensive relative to a fair ratio, but the SWS DCF model tells a different story. On this view, the stock at $263.63 sits below an estimated future cash flow value of $369.88, which raises the question of which signal you put more weight on.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out UFP Technologies for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 42 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Conflicted about what all this means for UFP Technologies and your portfolio decisions? Take a close look at the underlying data, weigh both sides of the story, and see the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond UFP Technologies?

If UFP Technologies has you thinking more broadly about where to deploy your capital, do not stop here. Widen your search with structured stock ideas.

• Target potential value opportunities by scanning companies that screen as attractively priced versus quality using the 42 high quality undervalued stocks
• Strengthen your focus on financial resilience by reviewing companies highlighted in the solid balance sheet and fundamentals stocks screener (48 results)
• Spot future contenders early by tracking lesser known businesses surfaced in the screener containing 19 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.